EP Patent

EP4048260B1 — Combination of substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for use in treating a hematological malignancy

Assigned to Celgene Corp · Expires 2026-03-11 · 0y expired

What this patent protects

Patent listed against quizartinib-dihydrochloride.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP4048260B1
Jurisdiction: EP
Classification: —
Expires: 2026-03-11
Drug substance claim: No
Drug product claim: No
Assignee: Celgene Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.